11β-Hydroxysteroid Dehydrogenase

11β-Hydroxysteroid Dehydrogenase (11β-HSD) is an enzyme that plays a critical role in the metabolism of glucocorticoids, which are steroid hormones involved in the regulation of energy metabolism, immune response, and stress response. There are two main isoforms of this enzyme, 11β-HSD1 and 11β-HSD2, each with distinct functions and tissue distributions.

Function

The primary function of 11β-HSD is to catalyze the interconversion between active cortisol and its inactive form, cortisone, in humans. In other species, such as rodents, the enzyme works on corticosterone and 11-dehydrocorticosterone. The direction of this conversion depends on the isoform of the enzyme:

• 11β-HSD1 predominantly reactivates cortisol from cortisone and is mainly expressed in liver and adipose tissue, as well as several other tissues. This isoform works in an NADPH-dependent manner.
• 11β-HSD2 primarily inactivates cortisol to cortisone and is highly expressed in mineralocorticoid-sensitive tissues such as the kidney, colon, and salivary glands. This isoform uses NAD+ as a cofactor.

Clinical Significance

The balance between these two isoforms is crucial for maintaining proper glucocorticoid and mineralocorticoid balance. Disruptions in this balance can lead to various health issues:

• Hypertension: Overactivity of 11β-HSD2 can lead to a syndrome known as apparent mineralocorticoid excess (AME), characterized by hypertension and hypokalemia. This is due to excessive conversion of cortisol to its inactive form, leading to an apparent excess of mineralocorticoids.
• Metabolic Syndrome: Increased activity of 11β-HSD1 in adipose tissue has been linked to obesity and metabolic syndrome, as it leads to higher levels of active glucocorticoids in the tissue, promoting fat deposition and insulin resistance.
• Congenital Adrenal Hyperplasia: Mutations affecting the 11β-HSD2 enzyme can result in congenital adrenal hyperplasia due to the excessive production of adrenal androgens.

Pharmacology

Given its role in regulating glucocorticoid activity, 11β-HSD has been a target for drug development, aiming to treat conditions like metabolic syndrome, diabetes, and hypertension. Inhibitors of 11β-HSD1 are being explored to reduce glucocorticoid action in target tissues, potentially ameliorating aspects of metabolic syndrome. Conversely, inhibitors of 11β-HSD2 could be used to treat conditions like AME by preventing the excessive inactivation of cortisol.

Research Directions

Research into 11β-HSD continues to uncover its broader implications in health and disease. Studies are exploring its role in the central nervous system, immune function, and its potential impact on chronic conditions such as depression and chronic fatigue syndrome. Understanding the precise mechanisms and effects of 11β-HSD isoforms in various tissues will be crucial for developing targeted therapies for a range of conditions.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian